Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Pharmacy | Monthly Briefing

Back to Journal Articles

October 2012 Briefing - Pharmacy

Last Updated: November 01, 2012.

 

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 

Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for October 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Once-Yearly Zoledronic Acid Benefits Men With Osteoporosis

WEDNESDAY, Oct. 31 (HealthDay News) -- For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)

Single Topical Ivermectin Head Lice Treatment Very Effective

WEDNESDAY, Oct. 31 (HealthDay News) -- A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day, according to a study published in the Nov. 1 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

FDA: Ameridose Issues Voluntary Recall of All Products

WEDNESDAY, Oct. 31 (HealthDay News) -- Ameridose, a Massachusetts-based manufacturer of sterile injectable products and oral syringes, is undergoing a voluntary recall of all unexpired products in circulation, according to an Oct. 31 news release issued by the U.S. Food and Drug Administration.

More Information

Greater Drop in LDL Seen With Atorvastatin + PCSK9 Antibody

WEDNESDAY, Oct. 31 (HealthDay News) -- Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) cholesterol levels compared with atorvastatin alone, according to a study published online Oct. 31 in the New England Journal of Medicine.

Abstract
Full Text

Sustained Release Naltrexone Effective, Safe for Opioid Users

WEDNESDAY, Oct. 31 (HealthDay News) -- Sustained release technologies for administering the opioid antagonist naltrexone (SRX) seem to be effective with an acceptable adverse event profile, according to a review published online Oct. 22 in the British Journal of Clinical Pharmacology.

Abstract
Full Text (subscription or payment may be required)

Latrepirdine Not Effective in Huntington's Disease

WEDNESDAY, Oct. 31 (HealthDay News) -- Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according to a study published online Oct. 29 in the Archives of Neurology.

Abstract
Full Text (subscription or payment may be required)

Only Omega-3s From Fish Tied to Lower Cerebrovascular Risk

WEDNESDAY, Oct. 31 (HealthDay News) -- Intake of omega-3 fatty acids from fish, but not circulating biomarkers or supplements, correlates with modestly reduced cerebrovascular risk, according to a meta-analysis published online Oct. 30 in BMJ.

Full Text
Editorial (subscription or payment may be required)

Program to Up Access to Combo Malaria Therapy Successful

WEDNESDAY, Oct. 31 (HealthDay News) -- Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines Facility-malaria (AMFm) has improved the availability, price, and market share of QAACTs, according to a study published online Oct. 31 in The Lancet.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

U.S. Medicare Spending on Elderly Has Outpaced Canada's

TUESDAY, Oct. 30 (HealthDay News) -- U.S. Medicare spending on the elderly has grown nearly three times faster than its Canadian counterpart, according to a study published online Oct. 29 in the Archives of Internal Medicine.

Full Text (subscription or payment may be required)

Resveratrol Has No Metabolic Benefit for Non-Obese Women

TUESDAY, Oct. 30 (HealthDay News) -- Resveratrol supplementation does not improve plasma lipids or insulin sensitivity in non-obese women, nor does it affect its putative targets in fat or muscle, according to a study published online Oct. 25 in Cell Metabolism.

Abstract
Full Text (subscription or payment may be required)

Potential Biomarker, Drug Target ID'd for Adult Leukemia

MONDAY, Oct. 29 (HealthDay News) -- Tumors from adults with B-cell precursor acute lymphoblastic leukemia (B-ALL) have epigenetic changes, leading to the identification of a potential biomarker and a possible drug target, according to research published online Oct. 29 in Cancer Discovery.

Abstract
Full Text (subscription or payment may be required)

More Intensive Chemo Ups Survival in Ewing Sarcoma

MONDAY, Oct. 29 (HealthDay News) -- More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma, according to a study published online Oct. 22 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)

Buspirone Improves Symptoms in Functional Dyspepsia

MONDAY, Oct. 29 (HealthDay News) -- Buspirone, a 5-hydroxytryptamine 1A receptor agonist, improves symptom severity in patients with functional dyspepsia (FD), according to a proof-of-concept study published in the November issue of Clinical Gastroenterology and Hepatology.

Abstract
Full Text

Synribo Approved to Treat Chronic Myelogenous Leukemia

FRIDAY, Oct. 26 (HealthDay News) -- Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML).

CML

Insulin Sensitivity Normally Highest After Breakfast

FRIDAY, Oct. 26 (HealthDay News) -- In healthy people without diabetes, glucose responsiveness tends to be higher after breakfast, which may have implications for the design of closed-loop insulin delivery systems for diabetes patients, according to a study published in the November issue of Diabetes.

Abstract
Full Text (subscription or payment may be required)

Timing of Hormone Therapy Use Impacts Alzheimer's Risk

THURSDAY, Oct. 25 (HealthDay News) -- Use of hormone therapy (HT) within five years of menopause is associated with a reduction in the risk of Alzheimer's disease (AD), according to a study published online Oct. 24 in Neurology.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Meta-Analysis: Antivirals Reduce Risk of Liver Cancer in Hep C

THURSDAY, Oct. 25 (HealthDay News) -- Antiviral treatment does significantly reduce the risk of developing liver cancer for patients with chronic hepatitis C infection, particularly in virological responders, according to a meta-analysis published online Oct. 22 in BMJ Open.

Abstract
Full Text

Insulin Glargine's Main Metabolic Effect As Metabolite M1

THURSDAY, Oct. 25 (HealthDay News) -- For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

Abstract
Full Text (subscription or payment may be required)

Terminal Cancer Patients May Have Erroneous Chemo Beliefs

WEDNESDAY, Oct. 24 (HealthDay News) -- Patients with stage IV metastatic cancer frequently do not understand that chemotherapy is unlikely to be curative, according to a study published in the Oct. 25 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Aspirin Improves Survival for CRC With PIK3CA Mutation

WEDNESDAY, Oct. 24 (HealthDay News) -- Among patients with colorectal cancer (CRC), regular use of aspirin after diagnosis is associated with longer survival for those with the mutated phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene (PIK3CA), according to a study published in the Oct. 25 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Fycompa Approved for Partial Onset Seizures

WEDNESDAY, Oct. 24 (HealthDay News) -- Fycompa (perampanel) tablets have been approved by the U.S. Food and Drug Administration to treat partial onset seizures in people aged 12 and older who have epilepsy.

epilepsy

Genuine Very Large Effects in Trials Rare in Medicine

TUESDAY, Oct. 23 (HealthDay News) -- Large treatment effects are most likely to be found in small studies, with the effect diminishing with additional trials, according to research published in the Oct. 24 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Antihypertensive Medication Use, BP Control Up in U.S.

TUESDAY, Oct. 23 (HealthDay News) -- Antihypertensive medication use and blood pressure control are increasing among U.S. adults, but racial disparities still exist, according to a study published in the Oct. 23 issue of Circulation.

Abstract
Full Text

TNF Inhibitor Use Doesn't Up Short-Term Cancer Incidence

MONDAY, Oct. 22 (HealthDay News) -- Treatment of chronic immune-mediated diseases with tumor necrosis factor (TNF) inhibitors does not result in any short-term increase in cancer incidence, compared with other commonly used therapies for these conditions, according to a study published online Oct. 10 in Arthritis & Rheumatism.

Abstract
Full Text (subscription or payment may be required)

HRT Not Recommended for Prevention of Chronic Conditions

MONDAY, Oct. 22 (HealthDay News) -- The benefits of hormone replacement therapy to prevent chronic conditions in postmenopausal women do not outweigh the harms, according to a recommendation statement from the U.S. Preventive Services Task Force (USPSTF) published online Oct. 23 in the Annals of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

Novel Liver X Receptor Agonist Benefits Diabetic Nephropathy

MONDAY, Oct. 22 (HealthDay News) -- A new therapeutic target that activates the liver X receptor (LXR) suppresses expression of inflammatory genes, including osteopontin, and improves kidney health and function in a mouse model of diabetes, according to a study published online Oct. 18 in the Journal of the American Society of Nephrology.

Abstract
Full Text (subscription or payment may be required)

Higher Calcium Intake May Lower Risk of Hyperparathyroidism

FRIDAY, Oct. 19 (HealthDay News) -- Women consuming higher levels of calcium are at lower risk of primary hyperparathyroidism, according to a study published online Oct. 18 in BMJ.

Full Text
Editorial (subscription or payment may be required)

Drug Approved for Symptomatic Vitreomacular Adhesion

THURSDAY, Oct. 18 (HealthDay News) -- Jetrea (ocriplasmin) has been approved by the U.S. Food and Drug Administration to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

this approval

Linezolid Beneficial in Drug-Resistant Tuberculosis

THURSDAY, Oct. 18 (HealthDay News) -- Adding linezolid to ongoing background therapy for the treatment of extensively drug-resistant (XDR) pulmonary tuberculosis is effective in achieving culture conversion, but patients must be carefully monitored for adverse events, according to research published in the Oct. 18 issue of the New England Journal of Medicine.

Abstract
Full Text

Ustekinumab Active for Some With Refractory Crohn's

THURSDAY, Oct. 18 (HealthDay News) -- Patients with moderate-to-severe Crohn's disease refractory to tumor necrosis factor (TNF) antagonists who receive ustekinumab induction therapy have a higher clinical response rate and, during maintenance therapy, achieve significantly higher response and remission rates compared to patients receiving placebo, according to a study published in the Oct. 18 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)

Stroke Risk Up With Serotonin Reuptake Inhibitor Use

THURSDAY, Oct. 18 (HealthDay News) -- Exposure to selective serotonin reuptake inhibitors (SSRIs) is associated with an increased risk of intracerebral and intracranial hemorrhage, according to a study published online Oct. 17 in Neurology.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Alzheimer's Symptoms Relapse Risk High After Halting Drug

WEDNESDAY, Oct. 17 (HealthDay News) -- Patients with Alzheimer's disease and psychosis or agitation-aggression who initially respond to antipsychotic drugs are more likely to relapse if treatment is discontinued, according to a study published in the Oct. 18 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)

High-Dose Vitamins Don't Halt HIV Progression, Death

TUESDAY, Oct. 16 (HealthDay News) -- High-dose vitamin supplementation does not reduce HIV disease progression or death among HIV patients initiating highly active antiretroviral therapy (HAART) in Tanzania, according to a study published in the Oct. 17 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

Lipid Profiles Improved in Past Two Decades in United States

TUESDAY, Oct. 16 (HealthDay News) -- Since 1988, levels of cholesterol and related lipids have been moving in a favorable direction among adults in the United States, even among the obese and those not taking lipid-lowering drugs, according to a study published in the Oct. 17 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

Lexatumumab Tolerated for Pediatric Solid Tumors

TUESDAY, Oct. 16 (HealthDay News) -- Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric patients with solid tumors, according to a study published online Oct. 15 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)

Zonisamide 400 mg Enhances Weight Loss for Obese

MONDAY, Oct. 15 (HealthDay News) -- The antiepileptic drug zonisamide, at a dosage of 400 mg per day, is associated with enhanced weight loss for obese patients when combined with diet and lifestyle counseling, but the incidence of adverse events is high, according to a study published online Oct. 15 in the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

B-Vitamin Supplement Doesn't Lower Colorectal Cancer Risk

MONDAY, Oct. 15 (HealthDay News) -- A combination of folic acid and vitamins B6 and B12 supplementation does not reduce the risk of colorectal adenoma among high-risk women, according to a study published online Oct. 12 in the Journal of the National Cancer Institute.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Seniors Overspending on Prescription Drug Plans

FRIDAY, Oct. 12 (HealthDay News) -- Recipients of Medicare Part D benefits have difficulty selecting the most cost-effective plan to cover their medication needs and, consequently, overpay by an average of $368 per year, with one-fifth overspending by $500 or more per year, according to research published in the October issue of Health Affairs.

Abstract
Full Text (subscription or payment may be required)

Methotrexate Use Linked to Reduced Mortality in RA

FRIDAY, Oct. 12 (HealthDay News) -- Use of methotrexate for one year or more is associated with a reduction in the risk of mortality for patients with rheumatoid arthritis (RA), according to a study published online Oct. 8 in Arthritis & Rheumatism.

Abstract
Full Text (subscription or payment may be required)

Tadalafil Effective, Safe in Complete Erectile Dysfunction

FRIDAY, Oct. 12 (HealthDay News) -- In men with complete erectile dysfunction (ED), tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in The Journal of Sexual Medicine.

Abstract
Full Text (subscription or payment may be required)

Abraxane Approved to Treat Advanced Lung Cancer

FRIDAY, Oct. 12 (HealthDay News) -- Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration -- in combination with the drug carboplatin -- to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday.

National Cancer Institute

PCI Linked to Increased Platelet Reactivity

FRIDAY, Oct. 12 (HealthDay News) -- Patients with coronary artery disease who receive percutaneous coronary intervention (PCI) have increased platelet reactivity after the procedure despite antiplatelet therapy, according to a study published online Oct. 5 in the Journal of Thrombosis and Haemostasis.

Abstract
Full Text (subscription or payment may be required)

Leflunomide Considered Safe, Effective for Psoriatic Arthritis

FRIDAY, Oct. 12 (HealthDay News) -- Leflunomide is effective for the treatment of patients with psoriatic arthritis (PsA) in daily clinical practice, according to a study published online Oct. 6 in Arthritis Care & Research.

Abstract
Full Text (subscription or payment may be required)

Drug Class Linked to Worse Outcomes After Transplant

FRIDAY, Oct. 12 (HealthDay News) -- Kidney transplant patients who receive mammalian target of rapamycin (mTOR) inhibitors after transplant have a greater probability of death or transplant failure than patients receiving calcineurin inhibitors, according to a study published online Oct. 1 in the American Journal of Transplantation.

Abstract
Full Text (subscription or payment may be required)

Social Media Influences Youth Sexual Behavior in Short Term

THURSDAY, Oct. 11 (HealthDay News) -- Social media can be an efficacious vehicle for delivering messages regarding the prevention of sexually transmitted infections (STIs), according to a study published online Oct. 9 in the American Journal of Preventive Medicine.

Full Text
Editorial

Use of More Costly Diabetes Medications Varies Widely

THURSDAY, Oct. 11 (HealthDay News) -- Even within an integrated Veterans Affairs (VA) system with a uniform national formulary and established criteria for drug use, there is substantial variation in the use of thiazolidinediones and long-acting insulin analogues among veterans with type 2 diabetes mellitus (T2DM), according to a research letter published online Oct. 8 in the Archives of Internal Medicine.

Full Text (subscription or payment may be required)

HIV Status Doesn't Influence Hodgkin's Lymphoma Outcome

THURSDAY, Oct. 11 (HealthDay News) -- Despite more extensive disease and more adverse prognostic factors, HIV-positive patients with Hodgkin's lymphoma (HL) do not have worse outcomes when treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to research published online Oct. 8 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)
Editorial

Study Confirms Link Between Analgesic Use, Ovarian Cancer

THURSDAY, Oct. 11 (HealthDay News) -- Use of any analgesic or aspirin correlates with a reduced risk of ovarian cancer, with the reduction significant only for use of any analgesic and serous ovarian cancer, according to a case-control study published in the September issue of ACTA Obstetricia et Gynecologica Scandinavica.

Abstract
Full Text (subscription or payment may be required)

Prior Alcohol Consumption Does Not Impair HCV Treatment

THURSDAY, Oct. 11 (HealthDay News) -- For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology.

Abstract
Full Text (subscription or payment may be required)

New Cervical Cancer Vaccine Targets HPV-Infected Women

WEDNESDAY, Oct. 10 (HealthDay News) -- A new candidate vaccine designed to prevent cervical dysplasia and cancer in women already infected with human papillomavirus (HPV) serotypes 16 and 18 is well tolerated and induces a robust immune response, according to a phase 1 study published in the Oct. 10 issue of Science Translational Medicine.

Abstract
Full Text (subscription or payment may be required)

Hormone Replacement Therapy Initiated Early Deemed Safe

WEDNESDAY, Oct. 10 (HealthDay News) -- For women who receive hormone replacement therapy soon after menopause, long-term cardiovascular outcomes are good, with no increase in the risk of any cancer, according to a study published online Oct. 9 in BMJ.

Full Text

Cannabis Relieves Muscle Stiffness in Multiple Sclerosis

WEDNESDAY, Oct. 10 (HealthDay News) -- Cannabis extract (CE) is effective at treating muscle stiffness in patients with multiple sclerosis (MS), according to a study published online July 12 in the Journal of Neurology, Neurosurgery & Psychiatry.

Abstract
Full Text

Review Compares Effectiveness of Tocolytic Agents

WEDNESDAY, Oct. 10 (HealthDay News) -- The most effective tocolytic agents for delaying delivery and improving neonatal and maternal outcomes are prostaglandin inhibitors and calcium channel blockers, according to a meta-analysis published online Oct. 9 in BMJ.

Full Text
Editorial (subscription or payment may be required)

Long-Term Ranibizumab Beneficial for Macular Edema

WEDNESDAY, Oct. 10 (HealthDay News) -- Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according to research published online Oct. 8 in the Archives of Ophthalmology.

Abstract
Full Text (subscription or payment may be required)

Diverse Forms of Distress Have Distinct Impact in Diabetes

WEDNESDAY, Oct. 10 (HealthDay News) -- In primary care patients with type 2 diabetes, depressive symptoms (DS) are predictive of future lifestyle-oriented self-management behaviors, while diabetes-related distress (DRD) predicts glycemic control, possibly due to medication adherence, according to research published online Oct. 1 in Diabetes Care.

Abstract
Full Text (subscription or payment may be required)

Belimumab Deemed Safe for Long-Term Treatment of Lupus

TUESDAY, Oct. 9 (HealthDay News) -- Belimumab is safe for long-term administration in the treatment of systemic lupus erythematosus (SLE), according to a study published in the October issue of Arthritis & Rheumatism.

Abstract
Full Text

Low-Dose Aspirin Use Shows Neuroprotective Effect in Women

TUESDAY, Oct. 9 (HealthDay News) -- Daily low-dose aspirin treatment may reduce global cognitive decline in older women at high risk for cardiovascular disease, according to a study published online Oct. 3 in BMJ Open.

Abstract
Full Text

Prenatal Psychotropic Meds Affect Infant Language

MONDAY, Oct. 8 (HealthDay News) -- Maternal mood and exposure to serotonin reuptake inhibitors (SRIs) in pregnancy affect development of the infant speech perception system, according to a study published online Oct. 8 in the Proceedings of the National Academy of Sciences.

Abstract
Full Text

New Drug Reduces Strokes After Aneurysm Surgery

MONDAY, Oct. 8 (HealthDay News) -- An investigational drug that disrupts neurotoxic signaling pathways is safe and effective in reducing strokes in patients undergoing surgery for a brain aneurysm, according to a study published online Oct. 8 in The Lancet Neurology.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Free Birth Control Substantially Lowers Abortion Rate

MONDAY, Oct. 8 (HealthDay News) -- Providing no-cost birth control, including long-acting reversible contraceptives (LARCs) such as intrauterine devices or implants, substantially reduces abortion rates and teenage pregnancies compared with the national rate, according to research published online Oct. 3 in Obstetrics & Gynecology.

Abstract
Full Text (subscription or payment may be required)

Opiate Substitution Cuts Risk of HIV for Injection Drug Users

FRIDAY, Oct. 5 (HealthDay News) -- Among people who inject drugs, opiate substitution treatment correlates with more than a 50 percent reduction in the risk of HIV infection, according to research published online Oct. 4 in BMJ.

Full Text
Editorial (subscription or payment may be required)

Larger Study Confirms Statins' Role in Preventing Cardiac Events

FRIDAY, Oct. 5 (HealthDay News) -- A large and unselected community-based study has confirmed the results of randomized controlled trials that have found persistent statin use to be beneficial for the primary prevention of acute cardiac events; the study was published online Sept. 27 in The American Journal of Cardiology.

Abstract
Full Text (subscription or payment may be required)

Lower Glaucoma Risk for Statin Users With Hyperlipidemia

THURSDAY, Oct. 4 (HealthDay News) -- For individuals with hyperlipidemia, statin use is associated with significant reductions in the risk of open-angle glaucoma (OAG), according to research published in the October issue of Ophthalmology.

Abstract
Full Text

Limiting the Problem of Missing Data Urged for Clinical Trials

WEDNESDAY, Oct. 3 (HealthDay News) -- Missing data compromise inferences from clinical trials, and due to the problematic nature of compensation with analysis methods, the importance of avoiding missing data in clinical trials is paramount, according to a special report published in the Oct. 4 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)

Cherry Intake Linked to Lower Risk of Recurrent Gout Attacks

WEDNESDAY, Oct. 3 (HealthDay News) -- Eating cherries or cherry extract is associated with a significantly lower risk of gout attacks, and this effect is intensified when cherry intake is combined with allopurinol use, according to research published online Sept. 28 in Arthritis & Rheumatism.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Mexiletine Shows Promise for Rare Nondystrophic Myotonias

WEDNESDAY, Oct. 3 (HealthDay News) -- There is preliminary evidence that mexiletine is effective for patients with rare nondystrophic myotonias (NDMs), according to a study published in the Oct. 3 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Study Finds β-Blockers May Not Reduce Cardiovascular Event Risk

TUESDAY, Oct. 2 (HealthDay News) -- For patients with coronary artery disease (CAD) risk factors alone, previous myocardial infarction (MI), or CAD without MI, β-blockers are not associated with a lower rate of cardiovascular events, according to a study published in the Oct. 3 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

High-Dose Vitamin D Does Not Prevent or Treat Colds

TUESDAY, Oct. 2 (HealthDay News) -- High monthly doses of vitamin D do not reduce the incidence or severity of upper respiratory tract infections (URTIs), according to a study published in the Oct. 3 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

New Guidelines Issued for Management of Gout

TUESDAY, Oct. 2 (HealthDay News) -- Approaches for management of gout are presented in a two-part guideline issued by the American College of Rheumatology (ACR) and published online Sept. 28 in Arthritis Care & Research.

Abstract - Part 1
Full Text (subscription or payment may be required)
Abstract - Part 2
Full Text (subscription or payment may be required)

No New Safety Concerns for Gardasil in Young Females

TUESDAY, Oct. 2 (HealthDay News) -- Since its approval in 2006, no new safety concerns have been found to be associated with vaccinating girls and young women with the quadrivalent human papillomavirus vaccine (HPV4), Gardasil, according to a study published online Oct. 1 in the Archives of Pediatrics & Adolescent Medicine.

Abstract
Full Text (subscription or payment may be required)

Sexual Dysfunction Common With Aromatase Inhibitors

MONDAY, Oct. 1 (HealthDay News) -- Sexual dysfunction is common among postmenopausal women treated with aromatase inhibitors after breast cancer, according to a study published online Sept. 17 in Menopause.

Abstract
Full Text (subscription or payment may be required)

Humira's Approval Widened to Include Ulcerative Colitis

MONDAY, Oct. 1 (HealthDay News) -- Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday.

ulcerative colitis

Melatonin Effective for Sleep in Patients Taking β-Blockers

MONDAY, Oct. 1 (HealthDay News) -- Patients taking β-blockers for hypertension, which can disturb sleep, have improved sleep quality with melatonin treatment, according to a study published in the Oct. 1 issue of SLEEP.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 ScoutNews, LLC. All rights reserved.


Previous: October 2012 Briefing - Pain Management Next: Mumps Outbreak Focused Within Male Orthodox Jewish Schools

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.